As the first-ever Medicare drug-price negotiations take shape, Big Pharma-backed Democrats want to limit the number of costly medicines regulators can target.
Democratic Reps. Scott Peters (Calif.), Wiley Nickel (N.C.), Josh Gottheimer (N.J.) and Donald Davis (N.C.) are each co-sponsoring at least one of several proposed bills that would limit regulators’ ability to negotiate down prices of drugs covered by the Medicare government insurance program. The legislation would erode the drug-pricing reforms included in the Democrats’ 2022 Inflation Reduction Act — efforts that Peters, Nickel, and Gottheimer supported. (Davis had not yet been elected to Congress.)
The four, who all hail from states with a major biotech or drug-industry presence, have together raked in more than $300,000 from pharmaceutical and health-products interests during the 2023-2024 congressional session. Gottheimer is reportedly eyeing a 2025 gubernatorial run in New Jersey, home to the pharmaceutical giant Merck & Co.
Recent Posts
‘A Day Without Immigrants’: Protests Against Trump’s Mass Deportation Plans Across U.S.
Take Action Now “D.C. depends deeply on immigrants, who work vital jobs in our local economy, pay taxes, and make the city a vibrant place to…
Fed Employee Unions Sue Over Musk’s Government Takeover
Take Action Now“It is disgraceful that the Trump administration has allowed unelected billionaires and their lackeys unfettered access to…
Trump’s Energy Pick Wants To Export Climate Destruction
Take Action NowChris Wright turns a real issue into a neat talking point for the destruction of the planet.By Gabriel Colburn, Foreign…
On Solidarity, Love, and Jewish Anti-Zionist Organizing, a Zero Hour Conversation with Rebecca Vilkomerson
Take Action Now The book and interview underscore the importance of long-term organizing, solidarity, and creating spaces for political and spiritual…